Why We Built This Is Why I'm High Without Reviews, Ads, or Sponsored Strains
How cannabis media's pay-to-play model fails consumers, and the science behind why independent education matters more than star ratings.
The Trust Problem Nobody Wants to Talk About
Cannabis reviews are broken. Not “a little unreliable” broken. Structurally broken.
In 2016, the Los Angeles Times ran an investigation into Weedmaps that should have ended the conversation about crowd-sourced strain reviews forever. Reporters found that more than 60% of Weedmaps reviews were suspected to be fake, and 70% of the 598 dispensaries they analyzed had reviews submitted from identical IP addresses [LA Times, 2016]. The consumer-protection service Fakespot later gave Weedmaps an F grade for review authenticity.
A decade later, nothing meaningful has changed. A 2025 420 Magazine analysis described the ongoing problem bluntly: “Astroturfing is coordinated, undisclosed, and intentionally misleading.” Public sentiment tracks the data — Leafly holds a 2.8/5 on Trustpilot (132 reviews), Weedmaps a 3.4/5 (258 reviews). Users regularly report that negative reviews get censored: “They repeatedly censored a comment I made that could’ve possibly, maybe been interpreted as lightly critical.”
When we sat down to design This Is Why I’m High, we asked a simple question: What would cannabis intelligence look like if we refused to play that game at all?
This article is the answer. It’s also a list of the things we will never build.
Reviews Encode Expectation, Not Chemistry
Even if every cannabis review were written by a real, unpaid human acting in perfect good faith, reviews would still be bad data. Here’s why.
A 2022 study on cannabis expectancy bias did something clever: researchers gave participants the same cannabis product but told half it was “indica” and half it was “sativa.” The result? Participants in the “indica” group reported more sedating effects. The “sativa” group reported more energizing effects. Same plant. Different label. Different experiences [cannabis expectancy study, 2022].
That’s not a small finding. It means the reviews you’re reading on Leafly or Weedmaps are measuring what people expected to feel, filtered through the marketing they saw on the way to the checkout counter. The star rating is a story about expectations. It’s not a measurement of chemistry.
It gets worse. Roughly 96% of all strains on major review platforms average 4 to 5 stars. When almost every product is “great,” the scale has no information content left. It’s a participation trophy. And your endocannabinoid system — the biology that actually determines how cannabis affects you — is as unique as your fingerprint. A review written by a stranger has almost no predictive power for your body.
We don’t think the solution is better reviews. We think reviews are the wrong instrument.
Pay-to-Play: The Part Users Don’t See
Here’s what the major cannabis platforms don’t put on their homepage: rankings are bought.
- Leafly charges dispensaries $750 to $10,000 per month for top listings.
- Weedmaps charges $420 to $30,000 per month for premium placements.
That “Top Dispensary Near You” carousel? That “Trending Strains” list? Those are advertising inventory. The user sees a recommendation. The platform sees a line item. The gap between those two things is where trust dies.
Again — this isn’t a moral judgment of the people who run those companies. Ad-supported media is a legitimate business model. What we’re saying is: we are not willing to build a cannabis intelligence platform on top of incentives that reward the highest bidder instead of the cleanest data. Those two goals don’t coexist. One always wins. And historically, it isn’t the user.
The Things We Will Never Build
We wrote this list down early and hung it on the wall. It’s our refusal manifesto — the features other platforms treat as table stakes, and that we treat as disqualifying.
| We Won’t Build | Why |
|---|---|
| Social features (reviews, likes, profiles) | Noise corrupts intelligence. A 4.6-star average doesn’t tell you anything your biology needs to know. |
| Ecommerce or delivery | We’re the brain, not the storefront. The moment we’re selling you product, we’re incentivized to shade the recommendation. |
| Medical diagnosis | Informational, not clinical. We teach the science. Your doctor handles your care. |
| Grow guides or cultivation content | Different audience, different mission. Cultivators deserve great resources — we’re not the ones to build them. |
| Advertising or sponsored strains | Recommendations must be unbiased. Period. No banners, no “featured” listings, no dollar signs pointing at specific cultivars. |
| Real-time menu scraping | Commodity data. Our moat is interpretation — what the chemistry means for you — not who has OG Kush in stock right now. |
Every one of these refusals has a cost. Social features would boost engagement metrics. Ecommerce would print money. Menu scraping would fill out our SEO footprint. We know. We’re okay with that.
Noise corrupts intelligence. That’s the whole thesis.
What You Get Instead
When you strip out reviews, ads, and sponsored strains, you’re left with a very different product. Here’s what This Is Why I’m High actually does:
- High Families — a terpene-driven classification system built from lab chemistry, not vibes. Limonene-forward strains cluster. Myrcene-forward strains cluster. You learn the chemistry once and it works in every state, every dispensary, every brand.
- Science-backed strain pages — cannabinoids, terpenes, cited research, and effect predictions rooted in pharmacology rather than crowd-sourced star ratings.
- Private, on-device intelligence — your stash, orders, and notes are yours. User data is never sold or used for ads. Period. Privacy is sacred, not a toggle in a settings screen.
- Unbiased recommendations — because there’s no sponsor list, there’s nothing to protect. If a strain is underwhelming, we say so.
We’d rather be the trusted brain for a small, serious community than the loudest billboard in a noisy market.
Our Strain Page vs. a Leafly Strain Page
Here’s the contrast, stripped to its essentials.
| A typical Leafly strain page | Our strain page |
|---|---|
| Star rating averaged from reviews, most 4-5 stars | No star rating. Strains aren’t products to be scored. |
| “Feels like: Happy, Relaxed, Euphoric” (emoji survey) | Dominant terpenes, cannabinoid ratios, High Family assignment |
| Sponsored dispensary carousel below the fold | No ads. No sponsored results. Ever. |
| User reviews that reward loud voices and brand loyalty | Cited research and chemistry the reader can verify |
| “Indica / Sativa / Hybrid” taxonomy | Terpene-based classification grounded in current pharmacology [Russo, 2011] |
| Recommendations shaped by ad inventory | Recommendations shaped by your own biology and preferences |
Both pages are trying to help you pick a strain. Only one of them starts from a position of honesty about why the page exists.
The Trade-Off, Stated Plainly
Refusing to build the standard cannabis media playbook has real costs, and we want to name them out loud:
- Slower growth. No viral reviews section, no affiliate flywheel, no paid placements to goose the rankings.
- A smaller database of “community hype.” We’re not counting fire emojis. We’re counting terpene data.
- No advertising revenue. We have to find other ways to pay for the work — subscriptions, integrations, products that align with the mission.
We are completely fine with that trade. A platform you can trust is worth more than a platform everyone uses.
The thesis: Intelligence over opinions. Science over marketing. Trust as a product, not a footnote.
Key Takeaways
- The mainstream cannabis review economy is structurally compromised — fake reviews (60%+ on Weedmaps per LA Times), pay-to-play rankings ($750–$30,000/month), and censored criticism are documented, ongoing realities.
- Reviews measure expectation, not chemistry. Label-based expectancy bias is well documented; identical products produce different reported experiences based on what the label says.
- 96% of strains averaging 4-5 stars means the scale is meaningless. There’s no signal left.
- This Is Why I’m High refuses social features, ads, sponsored strains, ecommerce, and menu scraping — because each one introduces incentives that corrupt the recommendation.
- Your endocannabinoid system is uniquely yours. Learning terpene chemistry and High Families gives you durable, portable knowledge that works anywhere, with any brand.
FAQs
Isn’t “no ads, no sponsors” just bad business?
Probably, by traditional metrics. We’d rather build a smaller product people trust than a bigger product people tolerate. If that trade doesn’t pencil out, the product shouldn’t exist.
Are Leafly and Weedmaps scams?
No. They’re ad-supported platforms doing what ad-supported platforms do. Our critique is about the business model and the incentives it creates — not the people building them. We just don’t want to play that game.
How does This Is Why I’m High make money, then?
Subscriptions and aligned products. Any AI-powered feature sits behind the Pro tier. We’d rather charge the people who value the work than monetize attention with banner ads.
Doesn’t removing reviews lose useful community knowledge?
Some, yes. But peer experience is already noisy because of expectancy bias and fake-review saturation. We’d rather give you the chemistry — which is verifiable — than a crowd-sourced average that encodes mostly marketing.
Is the indica/sativa distinction completely useless?
It’s a rough shorthand at best. Genetically and chemically, decades of crossbreeding have eroded the distinction. Terpene profiles predict experience more reliably [Russo, 2011]. That’s why we built High Families instead.
Sources
- Ryan, H. (2016). “Pot website Weedmaps found rife with fake reviews.” Los Angeles Times.
- 420 Magazine. (2025). “Astroturfing and fake reviews in cannabis media.” 420 Magazine Editorial.
- Trustpilot. “Leafly” and “Weedmaps” company review pages (accessed 2026).
- Cannabis expectancy study. (2022). Peer-reviewed research on indica/sativa label effects on subjective experience.
- Russo, E.B. (2011). “Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.” British Journal of Pharmacology, 163(7), 1344-1364. PMID: 21749363.
- Fakespot. Weedmaps review authenticity grade (F).
